Nolan A Wages

List of Publications by Year
in descending order

68 papers	1,172 citations	471509 17 h-index	477307 29 g-index
72 all docs	72 docs citations	72 times ranked	1060 citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of dose feasibility on the conduct of phase I trials of adoptive cell therapy. Contemporary Clinical Trials Communications, 2022, 25, 100877.	1.1	1
2	Change in parathyroid hormone levels from baseline predicts hypocalcemia following total or completion thyroidectomy. Head and Neck, 2022, , .	2.0	1
3	Adaptive Phase 1 Design in Radiation Therapy Trials. International Journal of Radiation Oncology Biology Physics, 2022, 113, 493-499.	0.8	1
4	Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1254-1262.	0.8	11
5	Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician. JCO Precision Oncology, 2021, 5, 317-324.	3.0	9
6	Reply to M. Ratain. JCO Precision Oncology, 2021, 5, 937-938.	3.0	0
7	Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. , 2021, 9, e002273.		39
8	Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma. Journal of Neuro-Oncology, 2021, 154, 41-47.	2.9	4
9	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
10	Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols. Contemporary Clinical Trials, 2021, 108, 106517.	1.8	6
11	Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trial. Clinical Trials, 2021, 18, 314-323.	1.6	1
12	Dose Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. Blood Advances, 2021, , .	5.2	5
13	Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer. International Journal of Environmental Research and Public Health, 2021, 18, 11452.	2.6	1
14	IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival. American Journal of Surgical Pathology, 2021, 45, 787-795.	3.7	6
15	Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma. Cells, 2021, 10, 3378.	4.1	24
16	Flexible Phase I–II Design for Partially Ordered Regimens with Application to Therapeutic Cancer Vaccines. Statistics in Biosciences, 2020, 12, 104-123.	1.2	3
17	Coherence principles in interval-based dose finding. Pharmaceutical Statistics, 2020, 19, 137-144.	1.3	3
18	Tailoring early-phase clinical trial design to address multiple research objectives. Cancer Immunology, Immunotherapy, 2020, 69, 95-102.	4.2	4

#	Article	IF	Citations
19	Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy. Clinical Trials, 2020, 17, 157-165.	1.6	7
20	Efficient dose-finding for drug combination studies involving a shift in study populations. Contemporary Clinical Trials Communications, 2020, 17, 100519.	1.1	2
21	MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 585551.	2.8	7
22	STAT RAD: Prospective Dose Escalation Clinical Trial of Single Fraction Scan-Plan-QA-Treat Stereotactic Body Radiation Therapy for Painful Osseous Metastases. Practical Radiation Oncology, 2020, 10, e444-e451.	2.1	10
23	A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freundâ€™s adjuvant in melanoma patients. , 2019, 7, 163.		59
24	Generalization of the time-to-event continual reassessment method to bivariate outcomes. Journal of Biopharmaceutical Statistics, 2019, 29, 635-647.	0.8	2
25	Evaluation of irrational dose assignment definitions using the continual reassessment method. Clinical Trials, 2019, 16, 665-672.	1.6	0
26	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute, 2019, 111, 118-128.	6.3	49
27	Shift models for dose-finding in partially ordered groups. Clinical Trials, 2019, 16, 32-40.	1.6	15
28	Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design. Journal of Biopharmaceutical Statistics, 2019, 29, 333-347.	0.8	3
29	Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL). Blood, 2019, 134, 1535-1535.	1.4	7
30	Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. Blood, 2019, 134, 4027-4027.	1.4	0
31	Accuracy, Safety, and Reliability of Novel Phase I Designsâ€"Letter. Clinical Cancer Research, 2018, 24, 5482-5482.	7.0	2
32	Revisiting isotonic phase I design in the era of model-assisted dose-finding. Clinical Trials, 2018, 15, 524-529.	1.6	7
33	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. OncoImmunology, 2018, 7, e1490855.	4.6	10
34	A web tool for designing and conducting phase I trials using the continual reassessment method. BMC Cancer, 2018, 18, 133.	2.6	16
35	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
36	Bleeding Risk of Low-Molecular Weight Heparin Vs Direct Oral Anticoagulant in Patients with Intracranial Tumors. Blood, 2018, 132, 2524-2524.	1.4	1

#	Article	IF	Citations
37	Implementation of adaptive methods in early-phase clinical trials. Statistics in Medicine, 2017, 36, 215-224.	1.6	29
38	Identifying a maximum tolerated contour in two-dimensional dose finding. Statistics in Medicine, 2017, 36, 242-253.	1.6	13
39	Clinical outcomes of helical conformal versus nonconformal palliative radiation therapy for axial skeletal metastases. Practical Radiation Oncology, 2017, 7, e479-e487.	2.1	2
40	A web application for evaluating Phase I methods using a non-parametric optimal benchmark. Clinical Trials, 2017, 14, 553-557.	1.6	9
41	Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents. Clinical Cancer Research, 2017, 23, 7158-7164.	7.0	11
42	Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies. Cancer Immunology, Immunotherapy, 2017, 66, 33-43.	4.2	30
43	Performance of toxicity probability interval based designs in contrast to the continual reassessment method. Statistics in Medicine, 2017, 36, 291-300.	1.6	26
44	Designs for phase I trials in ordered groups. Statistics in Medicine, 2017, 36, 254-265.	1.6	11
45	Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. Statistics in Medicine, 2016, 35, 3760-3775.	1.6	23
46	Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. Cancer Immunology, Immunotherapy, 2016, 65, 1189-1199.	4.2	38
47	Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunology, Immunotherapy, 2016, 65, 1201-1212.	4.2	36
48	Cervical Cancer in Women Aged 35 Years and Younger. Clinical Therapeutics, 2016, 38, 459-466.	2.5	27
49	Practical designs for Phase I combination studies in oncology. Journal of Biopharmaceutical Statistics, 2016, 26, 150-166.	0.8	12
50	Tubular carcinoma of the breast: Institutional and SEER database analysis supporting a unique classification. Breast Disease, 2015, 35, 103-111.	0.8	14
51	Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience. Cancer Immunology, Immunotherapy, 2015, 64, 1531-1539.	4.2	10
52	Comments on 'Competing designs for drug combination in phase I dose-finding clinical trials' by M. Riviere, F. Dubois, S. Zohar. Statistics in Medicine, 2015, 34, 18-22.	1.6	8
53	A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies. Statistics in Medicine, 2015, 34, 3194-3213.	1.6	30
54	A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial. Pharmaceutical Statistics, 2015, 14, 302-310.	1.3	16

#	Article	IF	Citations
55	A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. Contemporary Clinical Trials, 2015, 41, 172-179.	1.8	21
56	Recent developments in the implementation of novel designs for early-phase combination studies. Annals of Oncology, 2015, 26, 1036-1037.	1.2	8
57	Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents. Journal of Biopharmaceutical Statistics, 2015, 25, 903-920.	0.8	54
58	Strategic evaluation of interventions to prevent consequential late proctitis after prostate radiation therapy. Cancer Biology and Therapy, 2014, 15, 361-364.	3.4	2
59	Comments on â€˜A doseâ€ finding approach based on shrunken predictive probability for combinations of two agents in phase I trialsâ€™ by Akihiro Hirakawa, Chikuma Hamada, and Shigeyuki Matsui. Statistics in Medicine, 2014, 33, 2156-2158.	1.6	0
60	Phase I design for completely or partially ordered treatment schedules. Statistics in Medicine, 2014, 33, 569-579.	1.6	19
61	Phase I/II adaptive design for drug combination oncology trials. Statistics in Medicine, 2014, 33, 1990-2003.	1.6	36
62	Using the timeâ€ toâ€ event continual reassessment method in the presence of partial orders. Statistics in Medicine, 2013, 32, 131-141.	1.6	17
63	pocrm: An R-package for Phase I trials of combinations of agents. Computer Methods and Programs in Biomedicine, 2013, 112, 211-218.	4.7	17
64	Performance of two-stage continual reassessment method relative to an optimal benchmark. Clinical Trials, 2013, 10, 862-875.	1.6	14
65	Specifications of a continual reassessment method design for phase I trials of combined drugs. Pharmaceutical Statistics, 2013, 12, 217-224.	1.3	32
66	Obtaining the Optimal Dose in Alcohol Dependence Studies. Frontiers in Psychiatry, 2012, 3, 100.	2.6	2
67	Continual Reassessment Method for Partial Ordering. Biometrics, 2011, 67, 1555-1563.	1.4	144
68	Dose-finding design for multi-drug combinations. Clinical Trials, 2011, 8, 380-389.	1.6	81